{"pmid":32399895,"title":"Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.","text":["Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.","Int J Hematol","Takami, Akiyoshi","32399895"],"journal":"Int J Hematol","authors":["Takami, Akiyoshi"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399895","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s12185-020-02888-9","e_drugs":["Etoposide"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494847418368,"score":9.490897,"similar":[{"pmid":32474804,"title":"Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.","text":["Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.","Int J Hematol","Loscocco, Giuseppe G","32474804"],"journal":"Int J Hematol","authors":["Loscocco, Giuseppe G"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474804","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s12185-020-02895-w","weight":0,"_version_":1668341932665864192,"score":67.79777},{"pmid":32307298,"pmcid":"PMC7162634","title":"Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.","text":["Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.","The diagnosis of hemophagocytic lymphohistiocytosis (HLH) with cerebral involvement is challenging given the rarity of HLH and its resemblance to the much more common severe sepsis. Timely diagnosis and treatment may be lifesaving. We report two cases demonstrating different and rare forms of severe brain involvement in adult patients with HLH: acute necrotizing encephalopathy, and diffuse hemorrhagic disease due to disseminated intravascular coagulation. Severe HLH with brain involvement in adults is rare. HLH with cerebral involvement should be considered in patients presenting with severe systemic inflammatory response syndrome (SIRS) but negative cultures and unusual or unexpectedly severe clinical and/or radiologic signs of cerebral dysfunction. Similar brain injury may occur in patients with cytokine storm syndrome due to COVID-19. BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) presents with fevers, rash, organomegaly, cytopenia, and increased triglycerides and ferritin (Ramos-Casals et al., 2014) [1]. Neurologic abnormalities are reported in about one-third of patients (Cai et al., 2017), including a few cases of acute necrotizing encephalopathy (ANE) (Xiujuan et al., 2015). Coagulation abnormalities are frequent in HLH patients (Valade et al., 2015). OBJECTIVE: To raise awareness about the importance of early diagnosis and treatment of HLH with neurological involvement to prevent serious complications and demise.","J Clin Neurosci","Radmanesh, Farid","Rodriguez-Pla, Alicia","Pincus, Michael D","Burns, Joseph D","32307298"],"abstract":["The diagnosis of hemophagocytic lymphohistiocytosis (HLH) with cerebral involvement is challenging given the rarity of HLH and its resemblance to the much more common severe sepsis. Timely diagnosis and treatment may be lifesaving. We report two cases demonstrating different and rare forms of severe brain involvement in adult patients with HLH: acute necrotizing encephalopathy, and diffuse hemorrhagic disease due to disseminated intravascular coagulation. Severe HLH with brain involvement in adults is rare. HLH with cerebral involvement should be considered in patients presenting with severe systemic inflammatory response syndrome (SIRS) but negative cultures and unusual or unexpectedly severe clinical and/or radiologic signs of cerebral dysfunction. Similar brain injury may occur in patients with cytokine storm syndrome due to COVID-19. BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) presents with fevers, rash, organomegaly, cytopenia, and increased triglycerides and ferritin (Ramos-Casals et al., 2014) [1]. Neurologic abnormalities are reported in about one-third of patients (Cai et al., 2017), including a few cases of acute necrotizing encephalopathy (ANE) (Xiujuan et al., 2015). Coagulation abnormalities are frequent in HLH patients (Valade et al., 2015). OBJECTIVE: To raise awareness about the importance of early diagnosis and treatment of HLH with neurological involvement to prevent serious complications and demise."],"journal":"J Clin Neurosci","authors":["Radmanesh, Farid","Rodriguez-Pla, Alicia","Pincus, Michael D","Burns, Joseph D"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307298","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jocn.2020.04.054","keywords":["acute necrotizing encephalopathy","adult onset still's disease","diffuse hemorrhagic encephalopathy","disseminated intravascular coagulation","hemophagocytic syndrome"],"locations":["organomegaly","cytopenia"],"e_drugs":["Triglycerides"],"topics":["Case Report"],"weight":1,"_version_":1666138491286716416,"score":60.813885},{"pmid":32411313,"pmcid":"PMC7221383","title":"FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.","text":["FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.","Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients-- seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands-- with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury and hepatobiliary dysfunction. At the end-of-treatment, ICU patients had less need for vasopressors, significantly improved respiratory function and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore and support the need for larger clinical studies to validate this concept.","Cell Host Microbe","Dimopoulos, George","de Mast, Quirijn","Markou, Nikolaos","Theodorakopoulou, Maria","Komnos, Apostolos","Mouktaroudi, Maria","Netea, Mihai G","Spyridopoulos, Themistoklis","Verheggen, Rebecca J","Hoogerwerf, Jacobien","Lachana, Alexandra","van de Veerdonk, Frank L","Giamarellos-Bourboulis, Evangelos J","32411313"],"abstract":["Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients-- seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands-- with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury and hepatobiliary dysfunction. At the end-of-treatment, ICU patients had less need for vasopressors, significantly improved respiratory function and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore and support the need for larger clinical studies to validate this concept."],"journal":"Cell Host Microbe","authors":["Dimopoulos, George","de Mast, Quirijn","Markou, Nikolaos","Theodorakopoulou, Maria","Komnos, Apostolos","Mouktaroudi, Maria","Netea, Mihai G","Spyridopoulos, Themistoklis","Verheggen, Rebecca J","Hoogerwerf, Jacobien","Lachana, Alexandra","van de Veerdonk, Frank L","Giamarellos-Bourboulis, Evangelos J"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32411313","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.05.007","keywords":["anakinra","covid-19","ferritin","hemophagocytic lymphohistocytosis","respiratory function"],"locations":["Greece"],"countries":["Greece"],"countries_codes":["GRC|Greece"],"topics":["Treatment"],"weight":1,"_version_":1666897319084163073,"score":60.700584},{"pmid":32468178,"title":"Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.","text":["Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.","Int J Hematol","Takami, Akiyoshi","32468178"],"journal":"Int J Hematol","authors":["Takami, Akiyoshi"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468178","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s12185-020-02896-9","weight":0,"_version_":1668167109950046209,"score":57.83507},{"pmid":32416415,"title":"Etoposide-based therapy for severe forms of COVID-19.","text":["Etoposide-based therapy for severe forms of COVID-19.","The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.","Med Hypotheses","Hamizi, Kamel","Aouidane, Souhila","Belaaloui, Ghania","32416415"],"abstract":["The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19."],"journal":"Med Hypotheses","authors":["Hamizi, Kamel","Aouidane, Souhila","Belaaloui, Ghania"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416415","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109826","keywords":["covid-19","etoposide","hlh","haemophagocytic lymphohistiocytosis"],"topics":["Treatment"],"weight":1,"_version_":1666991242661068800,"score":49.330837}]}